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Abstract: Three new Lycopodium alkaloids, obscurumines C–E (1–3), along with nine known compounds, were isolated from the 
club moss Lycopodium obscurum L. Structures of the new compounds were determined on the basis of their spectroscopic analysis 
and the relative configurations of 1 were established by X-ray crystallographic analysis. All the new isolates were tested for the  
acetylcholinesterase (AChE) inhibitory activity. 
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Introduction 
The Lycopodium alkaloids represent a large family of plant 
secondary metabolites obtained from the club moss belonging 
to Lycopodiaceae.1,2 Since the impressively diverse skeletons 
and interesting biological activities, these alkaloids continue to 
be of interest from a biogenetic and biological point of view 
and some of them have been challenging targets for total  
synthesis.3–5 Lycopodium obscurum L., one of the club moss, 
has been used in China as a traditional folk medicine for the 
treatment of contusion, dysmenorrhea, quadriplegia, and ar-
thritic pain.6,7 Previously phytochemical investigation indicat-
ed triterpenoids were the main compounds of this plant and 
only few Lycopodium alkaloids were isolated.8–10 As part of an 
ongoing program aimed at discovering structurally interesting 
and bioactive Lycopodium alkaloids,11,12 three new Lycopodium
alkaloids, obscurumines C–E (1–3), along with nine known 
compounds, were isolated from the whole herb of L. obscurum 
L. Herein, we report the isolation, structure elucidation, and 
acetylcholinesterase (AChE) inhibitory activity of the new 
isolates. 
 
Results and Discussion 
The alkaloidal extract of L. obscurum was separated by 
normal-phase silica gel, RP-18 silica gel, HPLC, and Sephadex
LH-20 chromatography to afford three new Lycopodium  
alkaloids, obscurumines C–E (1–3), along with nine known 
compounds. The structures of known compounds, compared 
with literatures data, were identified as lycopodine,13  
anhydrolycodoline,14 obscurinine,9 obscurinine B,8 lycoflex-
ine,15 acetyldihydrolycopodine,16 (+)-acetylfawcettiine,17 N-
demethyl-α-obscurine,18 N-demethyl-β-obscurine.19 
Obscurumine C (1), colorless crystals, has a molecular  
formula C16H19NO3 as established by HREIMS at m/z 
273.1359 [M+] (calc. 273.1365), indicating eight degrees of 
unsaturation. The IR absorptions at 1710, 1685, and 1658 cm–1 
implied the presence of carbonyl groups. Analysis of the 1H 
and 13C NMR spectra of 1 (Table 1) revealed 16 carbon signals 
due to five quaternary carbons (three ketone carbons, one  
olefinic carbon, and one sp3 quaternary carbon), four methine 
groups (one olefinic carbon), six methylene groups, and one 
methyl group (H 0.71, d, J = 5.9 Hz). The 1H-1H COSY  
correlations revealed the existence of two fragments, a (C-
1‒C-4) and b (C-6‒C-8, C-8/C15/C-14, C-15‒C-16), as shown 
in Figure 2. In the HMBC spectrum, the correlations of the 
proton (H 2.42, H-4) at the terminal carbon (C-4) of fragment 
a and the protons (H 2.71, 2.39, H-6) at the terminal carbon 
(C-6) of fragment b with the carbonyl carbon (C-5, C 205.7) 
indicated the connection of C-4/C-5/C-6. While, the connection
of C-4/C-13/C-14 were derived from HMBC cross-peaks of  
H-4 and H-14 to C-13. Meanwhile, the HMBC correlations of 
H-1 with C-9 and C-13 established the connections of C-1,  
 
Figure 1.  Chemical structure of isolated compounds 1–3 
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C-9, and C-13 through a nitrogen atom. The above analysis 
indicated 1 should be a lycopodine-type alkaloid with many 
similarities to that of anhydrolycodoline,14 a known compound 
also isolated during the isolation. The obvious differences 
were that 1 possessed two more carbonyl groups one of which 
was connected to C-9 (C 155.8) as deduced from the HMBC 
correlations of H-1 and H-11 with C-9. The other carbonyl 
group was speculated to attached at C-10 according to the 13C 
chemical shift and confirmed by the HMBC correlations of  
H-11 to C-10. Thus, the gross structure of obscurumine C (1) 
was elucidated to be 1 possessing a lycopodine-type skeleton 
with a scarce two adjacent ketones unit. 
The relative configuration of 1 was established by ROESY 
experiment. In the ROESY spectrum, the correlations of H-4 
with H-6b and H-6a with H-15 were observed which indicated 
the α-orientation of H-4 and Me-16. Since the two adjacent 
ketone unit is scarce in Lycopodium alkaloid and to confirm 
the structure and the relative configuration, a X-ray  
crystallographic analysis of 1 (Figure 2) was carried out which 
unambiguously certificated the structure and the relative  
configurations of compound 1. 
Compound 2 was obtained as colorless oil. The HREIMS 
analysis gave an m/z at 261.1735 ([M+]) (calc. 261.1729) that 
established the molecular formula C16H23NO2, corresponding 
to six degrees of unsaturation. The 13C NMR spectrum  
displayed 16 carbon signals due to one methyl, eight  
methylene, four methine, and three quaternary carbons. 
Among them, one sp3 quaternary carbon (C 96.5) was  
ascribed to the carbon (C-13) which bearing both an oxygen 
atom and a nitrogen atom and one sp2 quaternary carbons were 
attributable to the ketone group (C 218.2). Partial structures 
a–c (C-1–C-4, C-6–C-8/C-15, and C-9‒C-11) were deduced 
from 1H-1H COSY (Figure 3) of 2. Further detailed 2D NMR 
analysis suggested compound 2 was a fawcettimine-type  
alkaloid which was similar to that of fawcettimine.20 The  
obvious difference was that 2 has one oxygened methine group 
rather than a methylene group in fawcettimine, which was 
connected to C-10 as deduced from the 1H-1H COSY  
Table 1. 1H and 13C NMR data for 13 (δ in ppm and J in Hz) 
 
No. 
1a  2b  3c  
δC δH δC δH δC δH 
1a 36.6 CH2 4.51 (dd, 13.8, 3.9) 41.9 CH2 3.05 (m) 52.4 CH2 3.32 (dd, 13.5, 7.9) 
1b  2.79 (dt, 13.8, 3.1)  2.86 (m)  2.92 (dd, 13.5, 5.6) 
2a 24.4 CH2 1.73 (br. d, 16.3) 20.2 CH2 1.98 (m) 129.4 CH 5.72 (overlap) 
2b  1.31 (m)  1.47 (m)   
3a 19.0 CH2 1.99 (d, 16.3) 19.4 CH2 2.16 (m) 131.8 CH 5.64 (t, 10.8) 
3b  1.51 (overlap)  1.37 (m)   
4 57.1 CH 2.42 (dd, 10.9, 2.6) 46.4 CH 2.32 (dd, 11.8, 2.3) 47.1 CH 3.95 (dd, 10.8, 6.5) 
5 205.7 C  218.2 C  70.5 CH 3.83 (br. d, 6.1) 
6a 46.0 CH2 2.71 (dd, 20.5, 8.2) 42.0 CH2 2.28 (dd, 18.9, 8.0) 37.6 CH2 1.79 (m) 
6b  2.39 (d, 20.5)  1.93 (d, 18.9)  1.64 (dt, 13.8, 9.7) 
7 40.2 CH 3.04 (br. s) 38.2 CH 2.17 (m) 40.4 CH 2.34 (m) 
8a 43.2 CH2 1.80 (d,15.0) 34.3 CH2 1.39 (m) 30.8 CH2 2.49 (overlap) 
8b  1.34 (m)  1.39 (m)  2.10 (d, 19.4) 
9a 155.8 C  50.2 CH2 3.02 (m) 56.7 CH2 2.67 (d, 9.4) 
9b    2.58 (d, 8.2)  2.49 (overlap) 
10a 177.0 C  76.5 CH 4.68 (t, 4.7) 20.9 CH2 1.21 (dt, 11.0, 7.1) 
10b      1.21 (dt, 11.0, 7.1) 
11a 121.5 CH 6.25 (s) 39.5 CH2 1.73 (d, 12.2) 31.4 CH2 1.71 (m) 
11b    1.50 (m)  1.31 (m) 
12 167.3 C  57.9 C  57.4 C  
13 63.1 C  96.5 C  201.4 C  
14a 44.0 CH2 2.64 (d,16.3) 29.9 CH2 2.07 (dd, 15.0, 5.9) 124.1 CH 5.72 (overlap) 
14b  1.02 (t, 16.3)  1.69 (br. d, 15.0)   
15 24.5 CH 1.51 (overlap) 27.4 CH 2.21 (m) 158.9 C  
16 20.9 CH3 0.71 (d, 5.9) 19.2 CH3 1.20 (d, 7.4) 24.1 CH3 1.87 (s) 
N-CH3     43.1 CH3 2.29 (s) 
aRecorded in CDCl3 at 500 MHz for 1H and 125 MHz for 13C; bRecorded in CDCl3 at 600 MHz for 1H and 150 MHz for 13C; cRecorded in 
DMSO at 600 MHz for 1H and 150 MHz for 13C. 
 
Figure 2.  Key 2D NMR correlations and X-ray structure of 
compound 1 
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correlations of H2-9/H-10/H2-11 and confirmed by the HMBC 
correlations of H-10 with C-9, C-11, and C-12. Additional, the 
HMBC correlation of H-10 with C-13 as well as the molecular 
formula of 2 indicated the connection of C-10 and C-13 
through an oxygen atom. In ROESY spectrum, the cross peaks 
of H-2b/H-4 and H-4/H-14a were observed, which suggested 
H-4 was β-oriented. H-15 was determined to be axially oriented
based on the small coupling constant between H-15 and axial 
H-14a [dd, 15.0 (3JH14a-H14b), 5.9 (3JH14a-H15) Hz)] and the small 
coupling constant between H-15 and equatorial H-14b [br. d, 
15.0 (3JH14a-H14b) Hz]. Meanwhile, the relative configuration of 
H-10 was suggested to be α according to the rigidity of  
compound 2. Therefore, the structure of 2 was established as 
shown in Figure 1 and named as obscurumine D. 
Obscurumine E (3) has a molecular formula C17H25NO2  
according to the HREIMS [m/z 275.1891 ([M+]), calc. 
275.1885] spectrum, implying six degrees of unsaturation. The 
IR spectrum showed absorption bands for hydroxyl (3439 cm–1) 
and ketone (1640 cm–1) groups. The 13C NMR and DEPT  
spectra revealed the existence of seventeen carbons due to 
three quaternary carbons, six methine groups, six methylene 
groups, and two methyl groups. Detailed analysis of its 1D and 
2D NMR data suggested that 3 was similar to that of epi-
lobscurinol.18 The only difference was that the double bond 
between C-3/C-4 in epi-lobscurinol was shift to C-2/C-3 as 
deduced from the 1H-1H COSY correlations of H-1/H-2/H-
3/H-4 and confirmed by the HMBC correlations of H-2 with 
C-1 and C-4. In the ROESY spectrum, the correlations of H-
4/H-11b and H-5/H-7 were observed which suggested the  
relative configuration of 3 was the same as epi-lobscurinol. So, 
the structure of 3 was deduced and shown in Figure 1. 
The new compounds obscurumine C–E (1–3) were tested 
for acetylcholine esterase (AChE) inhibitory activity. However, 
none of them showed obvious activity. 
 
Experimental Section 
General Experimental Procedures. Melting points were 
obtained on an X-4 micro melting point apparatus. Optical 
rotations were measured on a JASCO-20C digital polarimeter. 
UV spectra were recorded using a Shimadzu UV-2401A  
spectrophotometer. IR spectra were obtained on a Tensor 27 
spectrometer with KBr pellets. 1D and 2D NMR spectra were 
performed on Bruker AM-400, DRX-500, or AVANCE III-
600 spectrometers with TMS as an internal standard. Mass 
spectra were taken on VG Auto Spec-3000 or API-Qstar-
Pulsar instruments. X-ray diffraction was performed on a 
Bruker APEX DUO diffractometer using graphitemonochro-
mated Mo Kα radiation. Column chromatography (CC) was 
performed using silica gel (100–200 and 200–300 mesh, 
Qingdao Marine Chemical Co. Ltd., Qingdao, China), MCI gel 
(CHP 20P, 75–150 μm; Mitsubishi Chemical Co., Japan), and 
Sephadex LH-20 (Amersham Pharmacia Biotech, Sweden). 
 
Plant Material. The whole plants of L. obscurum were  
collected from Guizhou Province, China, and identified by 
Professor Xiao Cheng. A voucher specimen (Lo 2011081501) 
was deposited with the State Key Laboratory of Phytochemistry
and Plant Resources in West China, Kunming Institute of 
Botany, Chinese Academy of Sciences. 
 
Extraction and Isolation. Air-dried and pulverised plants 
of L. obscurum were extracted three times with methanol  
under reflux at 50 °C and the combined extract was removed 
under vacuum to afford a viscous residue. The crude extract 
was adjusted at pH 2 with 10% hydrochloric acid and then 
partitioned twice with acetic ether. Water-soluble materials, 
which were adjusted at pH 10 with saturated NaOH, were  
extracted three times with chloroform. The chloroform-soluble 
materials (479 g) were chromatographed over silica gel CC 
(32 × 120 cm) eluting with a gradient mobile phase (petroleum 
ether-acetone 9:1, 8:2, 7:3, 6:4, then methanol) to give 3 major 
fractions, Fr.A–Fr.C. Fr.A (29 g) was chromatographed on a 
reversed-phase preparative MPLC (MCI, 70 × 460 mm)  
column using step-gradient elution with a mixture of  
methanol/water (v/v, 70% to 100% methanol) to give three 
subfractions, Fr.A1–Fr.A3. Fr.A1 (13 g) was separated by 
repeat silica gel CC (4.6 × 50 cm) and recrystalization to offer 
1 (230 mg) as well as anhydrolycodoline (2.1 g). Fr.B (159 g) 
was subjected to a reversed-phase preparative MPLC (MCI, 70 
× 460 mm) column with a mixture solvent of methanol/water 
(v/v, 40% to 100% methanol) to yield five subfractions. Fr.B3 
(41 g) was eluted on silica gel CC (6.0 × 60 cm) with acetic 
ether-acetone (92:8) to yield a large number of lycopodine (30 
g), obscurumine B (5.4 g), (+)-acetylfawcettiine (49 mg) and 
obscurinine (21 mg). Fr.B4 (1.2 g) was purified by repeat  
silica gel CC (2.6 × 40 cm) to afford 2 (46 mg). Fr.C (136 g) 
was subjected to gradient elution on a reversed-phase  
preparative MPLC (MCI, 70 × 460 mm) column using a mix-
ture solvent of methanol/water (v/v, 10% to 80% methanol) to 
yield three subfractions, Fr.C1–Fr.C3. Fr.C3 (4.2 g) was eluted 
with chloroform-methanol (4:1) on silica gel CC (3.0 × 40 cm) 
to yield N-demethyl-β-obscurine (890 mg). Fr.C2 (8.6 g) was 
separated on silica gel CC (4.0 × 40 cm) using petroleum 
ether-aceticether-diethylamine (10:1:1) to give acetyldihydrol-
ycopodine (173 mg), lycoflexine (286 mg) and another  
fraction which was eluted with chloroform-methanol (2:3) to 
yield 3 (36 mg) and N-demethyl-α-obscurine (938 mg). 
 
Obscurumine C (1): colorless crystal; mp 195–196 °C; 
[α]25.8D   – 58.8 (c 0.35, MeOH); UV (MeOH): λmax (log ε) 250 
(3.46), 201 (3.38) nm; IR (KBr): νmax 2964, 1710, 1685, 1658, 
1414, 1353, 1287, 1227 cm–1; 1H and 13C NMR data, see Table 
1; ESIMS: m/z 274 [M + H]+; HREIMS: m/z 273.1359 [M+] 
(calc. for C16H19NO3 273.1365). 
 
Obscurumine D (2): colorless oil; [α]25.8D   – 126.6 (c 0.18, 
MeOH); UV (MeOH): λmax (log ε) 204 (2.48) nm; IR (KBr): νmax 2932, 1737 (ketone) 1641, 1454, 1126 cm–1; 1H and 13C 
 
Figure 3.  Key 2D NMR correlations of compound 2
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NMR data, see Table 1; ESIMS: m/z 262 [M + H]+; HREIMS: 
m/z 261.1735 [M+] (calc. for C16H23NO2 261.1729). 
 
Obscurumine E (3): colorless oil; [α]25.8D   + 100.0 (c 0.15, 
MeOH); UV (MeOH): λmax (log ε) 238 (3.47) nm; IR (KBr): νmax 3439, 1640 cm–1; 1H and 13C NMR data, see Table 1; 
ESIMS: m/z 276 [M + H]+; positive ion HREIMS: m/z 
275.1891 [M+] (calc. for C17H25NO2 275.1885). 
 
Crystal Data for Obscurumine C (1): C16H19NO3, M = 
273.32; orthorhomic, space group P212121; a = 8.1260(8) Å, b 
= 12.8706 (12) Å, c = 12.9226 (12) Å,  = 90.00, β = 90.00, γ 
= 90.00, V = 1351.5 (2) Å3, Z = 4, μ (MoKα) = 0.093 mm–1, 
crystal dimensions 0.87 × 0.36 × 0.30 mm was used for 
measurement on a Bruker APEX DUO diffractometer using 
graphitemonochromated Mo Kα radiation. The total number of 
reflections measured was 9380, of which 4335, were observed, 
I > 2σ(I). Final indices: R1 = 0.0599, wR2 = 0.1719. 
Crystallographic data for the structure of 1 have been 
deposited in the Cambridge Crystallographic Data Centre 
(deposition number CCDC 908305). Copies of the data can  
be obtained free of charge from the CCDC via 
www.ccdc.cam.ac.uk. 
 
Acetylcholinesterase Inhibition. Acetylcholinesterase 
(AChE) inhibitory activity of the compounds isolated was 
assayed by the spectrophotometric method developed by 
Ellman et. al. with slightly modification.21 S-Acetylthiocholine 
iodide, S-butyrylthiocholine iodide,5,5′-dithio-bis-(2-nitro-
benzoic) acid (DTNB, Ellman's reagent), acetylcholinesterase 
derived from human erythrocytes were purchased from Sigma 
Chemical. Compounds were dissolved in DMSO. The reaction 
mixture (totally 200 μL) containing phosphate buffer (pH 8.0), 
test compound (50 μM), and acetyl cholinesterase (0.02 U/mL), 
was incubated for 20 min (30 °C). Then, the reaction was  
initiated by the addition of 40 μL of solution containing DTNB 
(0.625 mM) and acetylthiocholine iodide (0.625 mM) for 
AChE inhibitory activity assay, respectively. The hydrolysis 
of acetylthiocholine was monitored at 405 nm every 30  
seconds for one hour. Tacrine was used as positive control 
with final concentration of 0.333 μM. All the reactions were 
performed in triplicate. The percentage inhibition was  
calculated as follows: % inhibition = (E – S)/E × 100 (E is the 
activity of the enzyme without test compound and S is the 
activity of enzyme with test compound). 
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